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Hypoxia inducible factor (HIF) is the master oxygen sensor within cells and is central to
the regulation of cell responses to varying oxygen levels. HIF activation during hypoxia
ensures optimum ATP production and cell integrity, and is associated both directly and
indirectly with reactive oxygen species (ROS) formation. HIF activation can either reduce
ROS formation by suppressing the function of mitochondrial tricarboxylic acid cycle
(TCA cycle), or increase ROS formation via NADPH oxidase (NOX), a target gene of
HIF pathway. ROS is an unavoidable consequence of aerobic metabolism. In normal
conditions (i.e., physioxia), ROS is produced at minimal levels and acts as a signaling
molecule subject to the dedicated balance between ROS production and scavenging.
Changes in oxygen concentrations affect ROS formation. When ROS levels exceed
defense mechanisms, ROS causes oxidative stress. Increased ROS levels can also be a
contributing factor to HIF stabilization during hypoxia and reoxygenation. In this review,
we systemically review HIF activation and ROS formation in the brain during hypoxia and
hypoxia/reoxygenation. We will then explore the literature describing how changes in HIF
levels might provide pharmacological targets for effective ischaemic stroke treatment.
HIF accumulation in the brain via HIF prolyl hydroxylase (PHD) inhibition is proposed as
an effective therapy for ischaemia stroke due to its antioxidation and anti-inflammatory
properties in addition to HIF pro-survival signaling. PHD is a key regulator of HIF levels
in cells. Pharmacological inhibition of PHD increases HIF levels in normoxia (i.e., at
20.9% O2 level). Preconditioning with HIF PHD inhibitors show a neuroprotective effect
in both in vitro and in vivo ischaemia stroke models, but post-stroke treatment with
PHD inhibitors remains debatable. HIF PHD inhibition during reperfusion can reduce
ROS formation and activate a number of cellular survival pathways. Given agents
targeting individual molecules in the ischaemic cascade (e.g., antioxidants) fail to be
translated in the clinic setting, thus far, HIF pathway targeting and thereby impacting
entire physiological networks is a promising drug target for reducing the adverse effects
of ischaemic stroke.
Keywords: reactive oxygen species, hypoxia inducible factor, prolyl hydroxylase, hypoxia, brain, stroke,
reperfusion
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INTRODUCTION
Oxygen is the most important molecule of life and is essential
for a broad spectrum of physiological reactions that include, but
are not restricted to, cell metabolism, respiration and growth.
Oxygen is distributed unevenly throughout the body at levels
much lower than atmospheric oxygen concentrations (around
20.9%). Physiological oxygen concentrations vary depending
upon the precise anatomical location, and the typical range is
evidently between 1 and 14% oxygen or 7.6–110 mmHg in arterial
partial pressure of oxygen (pO2) (1% oxygen = 7.6 mmHg)
(Carreau et al., 2011; Stamati et al., 2011). In the brain,
pO2 is described as 33.8 ± 2.6 mmHg (4.4 ± 0.3%), where
the mean pO2 decreases with brain depth (Carreau et al.,
2011). Box 1 lists oxygen concentrations in different parts of
a live rat brain recorded via optical fiber luminescent oxygen
sensor, demonstrating uneven oxygen distribution in the brain
(Box 1) (Zhang et al., 2015). Atmosphere air oxygen pressure
can be referred to normoxia, while partial oxygen pressure in
normal physiological conditions is called “physioxia,” or termed
“physiologically relevant oxygen levels” (Carreau et al., 2011; Jež
et al., 2015). Hypoxia is defined as oxygen tensions below tissue
physioxia. Hypoxia is a pathologic state while physioxia is a
normal state. There are varying degrees of hypoxia which can be
sub-classified into mild, moderate and severe (Gozal et al., 2005).
At the cellular lever, in hypoxic conditions, cells respond by
shifting metabolism to glycolysis with an increase in catalytic
activity of a number of enzymes, including phosphofructokinase-
1 and pyruvate. Hypoxia reduces aerobic oxidative respiration
and decreases electron-transport rate in the mitochondria leading
Abbreviations: 2-OG, nitric oxide (NO), 2-oxoglutarate; BBB, blood brain
barrier; BNIP3, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; COX,
cytochrome c oxidase; DMOG, dimethyloxalylglycine; eNOS, endothelial nitric
oxide synthase; EPO, erythropoietin; ETC, electron transport chain; FIH, factor
inhibiting HIF; GAPDH, glyceraldehyde-3-P-dehydrogenase; GLUT1,3, glucose
transporter 1, 3; HIF, hypoxia inducible factor; HO-1, heme oxygenase 1; HREs,
hypoxia response elements; I/R, ischaemia/reperfusion; iNOS, inducible nitric
oxide synthase; IRS, insulin receptor substrate; miR-210, microRNA-210; mPTPs,
mitochondria permeability transition pores; mtROS, mitochondrial ROS; Nox,
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase; OGD, oxygen
and glucose deprivation; PDK1, pyruvate dehydrogenase kinase 1; PHD, prolyl
hydroxylase; Prxs, peroxiredoxins; pVHL, von Hippel-Lindau protein; RIRR, ROS-
induced ROS release; ROS, reactive oxygen species; siRNA, small interfering RNA;
SOD, superoxide dismutase; VEGF, vascular endothelia growth factor; WT, wild
type.
BOX 1 | Spatial distribution of oxygen content in the rat Brain.
Brain area Oxygen content (Torr)
Cortex 2.53 ± 0.71
Cingulate cortex 22.4 ± 8.02
Lateral ventricles 51.82 ± 16.24
Substantia nigra 3.24 ± 0.62
Bed nucleus of the stria terminalis 2.94 ± 0.42
CA1 2.27 ± 0.12
Dentate gyrus 12.09 ± 8.78
Third ventricle 44.11 ± 15.57
Thalamus 2.45 ± 0.35
to 1ψm reduction, increased reactive oxygen species (ROS)
generation, and enhanced nitric oxide (NO) synthase. Depending
on the severity (e.g., mild, moderate, or severe) and duration (e.g.,
acute, chronic, or intermittent) of the hypoxic state, cells may
adapt, undergo injury, or die. In response to hypoxia, hypoxia
inducible factor (HIF) is activated and upregulates hundreds
of human genes, whose functions range from angiogenesis,
glycolysis, and erythropoiesis to inflammation and remodeling.
The length of exposure to low oxygen pressure as well as the
existing signaling pathways within different cells dictates the
effect of HIF signaling pathways (Schönenberger and Kovacs,
2015). Therefore, activation or inhibition of HIF signaling
intermediates could serve as novel therapeutic strategies for
diseases where hypoxia is a common underlying condition such
as myocardial and cerebral ischaemia, anemia, tumorigenesis, etc.
In this review article, we review the interaction between HIF
signaling and ROS formation and explore emerging therapeutic
approaches involving HIF signaling in ischaemic stroke.
HIF SIGNALING PATHWAY
Hypoxia inducible factors are a transcription factor subset
responsible for gene expression regulation which initiates the
response to hypoxic conditions (Semenza, 2012). HIF exhibits
a hetero-dimeric constitution of HIFα and HIFβ (ARNT)
subunits. The HIFα subunit is located in the cytoplasm while
the β subunit is constitutively expressed and located within the
nucleus (Wang et al., 1995). Three different isoforms of HIFα
have been identified thus far. HIF1α was the original isoform
identified by affinity purification using oligonucleotides from the
erythropoietin (EPO) locus (Semenza and Wang, 1992) while
HIF2α and HIF3α were identified by homology searches or
through screening for interaction partners with HIF1α (Ratcliffe,
2007). HIF1α is ubiquitously expressed, and is a known regulator
of hypoxic adaption. HIF2α is tissue specific and is emerging as
a distinct entity in target gene induction in vascular endothelial
cells, and is known as the endothelial PAS domain protein/an
endothelium specific HIFα isoform (Tian et al., 1997; Hashimoto
and Shibasaki, 2015). HIF 2α shares 48% amino acid homology
with HIF1α and binds to similar promoter sites but differs in
the cofactors it recruits (Tian et al., 1997). HIF1 and HIF2 have
largely overlapping but also some non-redundant functions. HIF-
1α appears to be the most active isoform during short periods (2–
24 h) of intense hypoxia or anoxia (<0.1% O2) in some cell lines,
whereas HIF2α is active under mild or physiological hypoxia, and
continues to be active even after 48–72 h of hypoxia (Holmquist-
Mengelbier et al., 2006). Thus, in some contexts, HIF1α plays
key role in initial response to hypoxia whereas HIF2α drives the
hypoxic response during chronic hypoxic exposure (Holmquist-
Mengelbier et al., 2006; Koh et al., 2011). The role of HIF3α is
yet to be clearly defined, but may involve response to hypoxia
through regulation of other HIF isoforms (Makino et al., 2001).
During physioxia, HIFα subunits undergo hydroxylation
by prolyl-4-hydroxylase domain enzymes (PHDs). PHD
has 3 isoforms (PHD1-3) which share homology in the
C-terminal catalytic domain, but differ biochemically in their
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N-terminal sequences and functionally in terms of expression,
cellular localization, and their ability to hydroxylate HIF1
(Appelhoff et al., 2004; Fong and Takeda, 2008; Chen et al.,
2012). PHDs hydroxylate human HIFα at its C- and N-
terminal oxygen dependent degradation domains (CODD
and NODD). Hydroxylation of HIFα proteins allows von
Hippel-Lindau protein (pVHL) binding, leading to subsequent
HIFα polyubiquitination as pVHL is part of a E3 ubiquitin
ligase complex. Eventually, HIFα proteins are rapidly degraded
by proteasome (Ke and Costa, 2006). In addition, Factor
inhibiting HIF (FIH) hydroxylates an asparaginyl-residue in
the C-terminal transcriptional activation domain of HIFα
reducing the association of HIFα with transcriptional coactivator
proteins thus inhibiting HIF mediated transcription (Lando
et al., 2002). In hypoxia, activity of HIF PHD is reduced due to
a lack of oxygen, a cofactor of HIF PHD. HIFα accumulates in
the cytoplasm, and is translocated to the nucleus where the β
subunit locates, enabling dimerization with HIFβ to form the
HIF molecule. The HIF complex is activated when interacting
with the p300/CBP coactivators and then binds to HREs, leading
to upregulated transcription of HIF-target genes (Figure 1)
(Semenza, 2012). As a key regulator of hypoxic adaption, HIF
regulates more than 500 human genes with a significant variety
of biological functions regulated in a tissue-specific manner
(Geiger et al., 2011). The most prominent of these are affiliated
with angiogenesis promotion [vascular endothelia growth factor
(VEGF)]; glycolysis [pyruvate dehydrogenase kinase 1 (PDK1)];
cell proliferation and survival (insulin-like growth factor 2); EPO;
pH regulation (carbonic anhydrase 9); apoptosis/cell cycle arrest
(Bcl-2/BNIP3/p53); glucose metabolism [glucose transporter 1,
3 (GLUT1/3)] and vascular tone [heme oxygenase 1(HO-1)].
HIF1 is frequently associated with metabolic responses to
hypoxia, and preferentially induces glycolytic enzyme gene
expression (Hu et al., 2003), but also upregulates genes encoding
pro-death proteins, such as BCL2/adenovirus E1B 19 kDa
protein-interacting protein 3 (BNIP3); cyclooxygenase-2, or
p53 stabilization (Singh et al., 2012). Carbonic anhydrase 9 and
BNIP3 are HIF1 downstream genes, while HIF2 is the main
driver of EPO production (Ratcliffe, 2007; Percy et al., 2008).
VEGF and GLUT1,3 are both HIF1 and HIF2 downstream genes.
ROS FORMATION AT DIFFERENT
OXYGEN LEVELS
Reactive oxygen species are an inevitable byproduct in cellular
respiration, during which an electron escapes from the electron
transport chain (ETC) and bind to oxygen to form superoxide
anions (O2−). About 1–2% of O2 consumed by mitochondria is
used for ROS formation, mainly through ETC complexes I and III
(Tahara et al., 2009). In normal (e.g., non-ischaemic) cells, most
ROS (about 95%) are generated in the ETC, while the rest can
be formed by a group of enzymes, e.g., the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (Nox), monoamine
oxidase, mitochondrial BKCa and mKATP channels, cytochrome
b5 reductase, and dihydroorotate dehydrogenase (Meo et al.,
2016). Under normobaric and hyperbaric conditions, the rate
of the formation of a primary ROS (superoxide only) increases
with oxygen concentrations (Turrens, 1997; Genova et al., 2001;
Alvarez et al., 2003; Zorov et al., 2014). It was predicted that
the generation of ROS should decrease with the reduction in
oxygen concentration. However, a number of studies revealed
ROS is either constant or even increased when pO2 drops,
e.g., robust ROS formation under 1.5% O2 has been recorded
(Chandel et al., 1998; Waypa and Schumacker, 2002). During
hypoxia, cells change the oxidation of NAD-related substrates
(complex I) to succinate oxidation (complex II) (Lukyanova et al.,
2018). Previously complex II was not considered as a significant
contributor to production of ROS (Raha and Robinson, 2001),
however, more recently studies have reported that complex II
generates ROS when complex I/III are inhibited or succinate
concentrations are low (Quinlan et al., 2012). Complex II
can adapt to different roles as a producer or modulator of
mitochondrial ROS (mtROS) depending on substrate and activity
of other complexes, e.g., complex I, complex III (Dröse, 2013).
At low to moderate concentrations, ROS are involved
in defense against pathogens, cell signaling and mitogenic
responses; at higher concentrations, ROS causes oxidative
stress, a state where pro-oxidants and antioxidant substances
are imbalanced. DNA, cellular lipid and protein damage
can occur during oxidative stress (Valko et al., 2006),
resulting in impaired cell function and decreased cell
viability (Apostolova and Victor, 2015; Redza-Dutordoir
and Averill-Bates, 2016). As such, ROS could play a key
role in maintaining homeostasis by the regulation of various
physiological functions and the pathogenesis of various diseases
including: cancer, neurodegenerative diseases, cardiovascular
diseases, autoimmune disorders/inflammatory diseases and
diabetes mellitus (Apostolova and Victor, 2015).
In cells, there is an efficient anti-oxidative system comprised
of enzymatic as well as non-enzymatic antioxidants to maintain
tight control of ROS level to avoid any oxidative injury and not
to eliminate them completely (Sharma et al., 2012). Superoxide
dismutase scavenges the superoxide anion to form hydrogen
peroxide leading to diminished toxic effects. Catalase within
peroxisomes decomposes and reduces hydrogen peroxide levels
and protects cells from highly reactive hydroxyl radicals (Khan
et al., 2012). Glutathione peroxidase, reductase and transferase
are fundamental antioxidant enzymes being closely related to
the direct elimination of ROS (Khan et al., 2012). In the cytosol
or mitochondria, glutathione peroxidase detoxifies most of the
peroxides (Lubos et al., 2011). Peroxiredoxins (Prxs), a family
of antioxidant enzymes, are essential for redox homeostasis
(Olguín-Albuerne and Morán, 2018). Prxs can be released
extracellularly after ischemia and, paradoxically, become potent
proinflammatory signals that initiate a destructive immune
response in the brain (Shichita et al., 2012). Mao et al. (2017)
showed that Gastrodin-D inhibited the activity of Prxs and
prevented H2O2-induced oxidative injury in SH-SY5Y nerve
cells. The non-enzymatic antioxidant defense systems in the brain
compose of ascorbate, glutathione and vitamin E (Ohta et al.,
2012). These antioxidant molecules usually react with reactive
oxygen or nitrogen species to detoxify the later but they do not
prevent their formation (Arteaga et al., 2017).
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FIGURE 1 | Schematic diagram describing HIF pathway. At physioxia, HIFα is continuously produced and constantly hydroxylated by PHD1-3 at prolyl residue 402
and 564 of C- and N-terminal oxygen dependent degradation domains (CODD and NODD). The hydroxylated HIFα is then poly-ubiquitinated and is targeted for
proteosomal degradation by an E3 ubiquitin ligase – the von Hippel-Lindau protein (pVHL) complex, resulting in rapid proteasome degradation. In addition, FIH
hydroxylates an asparaginyl-residue in the C-terminal transcriptional domain of HIFα, inhibiting HIF mediated transcription; in hypoxia, activities of both PHD and FIH
are reduced due to a lack of oxygen. HIFα accumulates in the cytoplasm, and enters the nucleus where HIFα dimerizes with HIF β to form the HIF molecule. The HIF
complex is activated when interacting with the p300/CBP coactivators and then binds to HREs, leading to upregulating transcription of HIF downstream genes.
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ROS INDUCED HIF ACCUMULATION
Oxygen deficiency is a master inducer of HIF accumulation
but ROS and many other stress signals can also induce
HIF accumulation even at normoxia, so called pseudohypoxia
(Salminen et al., 2016). ROS has been found to be a contributing
factor in the stabilization of HIF-1α; ultimately allowing for
HIF pathway activation in a number of studies (Chandel et al.,
1998, 2000; Bell et al., 2007). A mutation in the respiratory
chain, complex 1 inhibitors, or a reduction of mtROS levels,
or an Inhibition of mitochondrial transcription factor A by
short hairpin RNA, prevented the stabilization of HIF-1α under
hypoxic conditions suggesting that generation of mtROS is
responsible for propagating the hypoxic signal (Chandel et al.,
1998; Agani et al., 2000; Bell et al., 2007). Addition of exogenous
H2O2 or mutations leading to H2O2 accumulation stabilizes HIF-
1α during normoxia (Chandel et al., 2000; Richard et al., 2000).
Similarly, antioxidants abolished the hypoxic HIF response
(Chandel et al., 1998).
Furthermore, a number of intermediates, e.g., nitric oxide
(NO), have been found to contribute to ROS mediated HIF1α
regulation (Movafagh et al., 2015). Metzen et al. (2003) found
NO−, a reactive nitrogen species, caused HIF-1α accumulation
in normoxia, due to decreased ubiquitination of HIF-1α, loss of
HIF-1α-pVHL interaction and inhibition of HIF PHDs. Inducible
nitric oxide synthase (iNOS) induced endogenous NO led to HIF
accumulation in both normoxia and hypoxia conditions (Mateo
et al., 2003). Additional pathway contributes to ROS mediated
HIF1α regulation is through inflammatory mediators (Zhou Y.Z.
et al., 2017). Increased synthesis of TNFα and IL-1β by exogenous
ROS increased HIF1α accumulation (Westra et al., 2007). ROS
generation caused the up-regulation of NF-κB, which in turn led
to HIF-1α mRNA induction in hypoxia (Lluis et al., 2007; Hagen,
2012).
Some studies have argued alternatively that mtROS does
not directly lead to the stabilization of HIF-1α (Hagen
et al., 2003; Doege et al., 2005; Chua et al., 2010), and
put forward the “oxygen-redirection” hypothesis where the
level of oxygen consumption in the mitochondria affects
the level of available intracellular oxygen (Wenger, 2006).
Thus, decreased oxygen consumption in mitochondria is
what leads to the paradoxical increase, or re-distribution, of
oxygen available to maintain PHD activity. Yang et al. (2012)
found that cells treated with sodium azide, an inhibitor of
mitochondrial complex IV, had HIF-1α stabilization blocked.
It has been suggested that inhibition of complex IV leads to
the redistribution of oxygen to PHD, etc.; ultimately leading to
the degradation of HIF-1α (Hagen et al., 2003). Doege et al.
(2005) found that cells (U2OS and 143B) with pharmacological
ETC inhibition, in oxygen-permeable dishes, HIF-1α was
stabilized in hypoxia, while in conventional polystyrene dishes,
ROS generation was reduced and HIF-1α was degraded.
This provided the ‘link’ between ROS and HIF activation.
Acker et al. (2006) suggested the increases of ROS and its
relationship with Fenton chemistry may decrease availability




A number of HIF downstream products are enzymes linked
to glucose/energy metabolism, e.g., glyceraldehyde-3-P-
dehydrogenase (GAPDH), PDK1, etc. (Kim et al., 2006).
PDK reduces the hypoxic ROS generation by decreasing
mitochondrial oxygen consumption through the inhibition
of pyruvate dehydrogenase from using pyruvate as fuel for
the mitochondrial TCA cycle (Kim et al., 2006). Increased
respiration efficiency in hypoxic cells can also come via
regulation of cytochrome c oxidase (COX) activity. There is a
switch from the COX4-1 regulatory unit of complex IV (COX
in ETC) in normoxic conditions to the COX4-2 unit under
hypoxic conditions by increasing both transcriptional activation
of the genes that encode COX4-2 and degradation of COX4-1
by activation of LON (a mitochondrial protease) (Fukuda et al.,
2007). Chan et al. (2009) noted that stabilization of HIF-1α in
hypoxia led to the expression of microRNA-210 (miR-210) and
subsequently decreased mitochondrial respiration resulting in
decreased ROS production. Increased expression of miR-210
results in repression of iron-sulfur cluster assembly proteins
(ISCU1/2), associated with electron transport and mitochondrial
oxidation-reduction reactions. Nevertheless, some studies have
found that HIF accumulation increases ROS generation. HIF-1α
stabilization activates gene expression of Nox1 and Nox2 which
generates superoxide (O2−), resulting in an increase of ROS
generation (Goyal et al., 2004; Yuan et al., 2011). HIF 1 could
either binds to NOX2 or upregulates Nox4-dependent ROS
formation (Diebold et al., 2010, 2012). In agreement hypoxia
has been shown to upregulate Nox2 mRNA expression in
brain cortex and stem in wild type (WT) mice but not in HIF2
heterozygous mice (Yuan et al., 2011) suggesting a HIF1, and
not HIF2, dependence. Peng et al. (2006) found that ROS was
increased in WT mice but absent in the HIF-1α heterozygous
mice under intermittent hypoxia. Studies conducted on Nox
isoforms, excluding Goyal’s, were based in intermittent hypoxic
conditions while studies which found a decrease in mtROS
generation were conducted in sustained hypoxia. Intermittent
hypoxia is more potent in activating HIF1 than sustained hypoxia
(Prabhakar, 2001). It is widely accepted that HIF activation helps
to maintain low levels of ROS in hypoxia by suppressing the
function of mitochondrial TCA cycle. Thus, HIF activation in
hypoxia ensures optimum ATP production and cell integrity
by minimizing ROS during hypoxia (Weidemann and Johnson,
2008).
ROS FORMATION AND HIF ACTIVATION
DURING REPERFUSION
During prolonged periods of hypoxia/ischaemia, ATP levels
and intracellular pH decrease due to anaerobic metabolism
and lactate accumulation. This ultimately leads to cell death
though various mechanisms including autophagy, apoptosis and
necrosis and necroptosis (Kalogeris et al., 2012). Paradoxically,
a sudden increase in oxygen does not prevent apoptosis.
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Instead, several studies have shown it may worsen outcomes
because of the generation of ROS (Chouchani et al., 2014). As
indicated previously, high levels of ROS cause oxidative stress,
affect oxidation of DNA and induce pro-apoptosis pathways
(Valko et al., 2006). During reperfusion, mitochondria not only
produce the high level of ROS but also open the mitochondria
permeability transition pores (mPTPs) (Webster, 2012), which
enhance the ROS formation, forming a vicious circle, so
called ROS-induced ROS release (RIRR) (Zorov et al., 2014).
Sustained mPTP formation by the recovery of pH and calcium
overload in reperfusion permits communication between the
cytoplasm and the mitochondrial matrix, but also increases
mitochondrial permeability to ions and other solutes with
molecular weights of 1.5 kD leading to the collapse of the
mitochondrial membrane potential and destruction (Kalogeris
et al., 2014). The destructive function of RIRR synergistically
increases post-ischaemic oxidative stress.
Abramov et al. (2007) identified three distinct phases of ROS
generation in primary rat neurons during oxygen and glucose
deprivation (OGD) and re-oxygenation. During the first few
minutes of ischaemia, an initial burst of ROS is generated due to
mitochondrial depolarization, which ceases when mitochondrial
potential is lost. During this phase, complex I and III are
major sites of ROS production (Turrens, 2003). The second
rise in ROS is attributable to activation of xanthine oxidase.
This rise occurs after a substantial delay and is correlated
with ATP depletion. ATP depletion results in conversion of
adenine nucleotides into xanthine and hypoxanthine, substrates
of xanthine oxidase. Mechanistic support comes from the
observations that xanthine oxidase inhibitors such as allopurinol
and oxypurinol decrease ROS levels (Abramov et al., 2007). The
final phase of ROS generation is during reoxygenation and is
a major contributor of reperfusion injury. During reperfusion,
calcium-dependent activation of Nox promotes ROS formation,
elevates glutamate release and excitotoxicity (Radermacher et al.,
2012; McCann and Roulston, 2013). Both genetically knockout
Nox4 (the most abundantly expressed Nox isoform in the
body) and pharmacologically inhibition of Nox by VAS2870
reduced brain injuries after cerebral ischaemia, although there
was not any augmented effects with a combination of both
treatments (Kleinschnitz et al., 2010). Conversely, mice with
Nox4 overexpression specifically in endothelium had larger I/R-
induced infarct size compared to WT mice (Arimura et al.,
2012).
Since mtROS generation contributes significantly for the
pathogenesis of I/R injury, anti-oxidation has been set as a
prime target in the treatment of ischaemic diseases (Smith et al.,
2012). NXY-059, an antioxidant, has been shown to reduce
the impact of cerebral ischaemia in preclinical studies (Green
and Shuaib, 2006). The SAINT I Clinical Trial reported that
NXY-059 treated within 6 h after the onset of symptoms in
ischaemic stroke patients significantly improved the outcome of
the patients than placebo (Lees et al., 2006a,b). However, the
SAINT II Trial, a larger randomized multicenter clinical trial of
the NXY-059, failed to demonstrate a treatment benefit in acute
ischaemic stroke halting further clinical development (Shuaib
et al., 2007). The negative results can be due to (i). NXY-059
weakly targets ROS only after they are formed; (ii). NXY-059 poor
penetrates blood brain barriers (BBB); and (iii). NXY-059 is lack
of synergism with rtPA (Amaro and Chamorro, 2011; McCann
and Roulston, 2013).
HIF AND PHD PHARMACOLOGICAL
MODULATION IN ISCHAEMIC STROKE
The use of compounds that act on individual targets of the
ischaemic cascade likely (e.g., ROS) fails to be translated
into clinical practice for treating ischaemic diseases (O’Collins
et al., 2006; Papadakis et al., 2013). An alternative to targeting
individual pathways is to target entire physiological networks
which influence a number of targets at one time and thereby
simultaneously suppress both ischaemic and reperfusion damage
(Chen, 2013). It is proposed that regulating HIF induction and
accumulation by inhibition of the activity of a family of 2-
oxoglutarate (2-OG)-dependent hydroxylase enzymes (PHD1-3)
is a highly promising therapeutic approach for ischaemic diseases
(Nagel et al., 2010; Chen et al., 2014). These 2-OG analogs when
given before ischaemia activate the HIF pathway in normoxic
conditions and prevent tissue damage from subsequent ischaemic
attack (Chen et al., 2014). This phenomenon is known as
pharmacology hypoxia preconditioning, whereby sub-threshold
insults increase resistance to subsequent injurious ischaemia.
A state of tolerance is established after preconditioning stimulus
in two temporal profiles: an acute phase due to rapid
post-translational modifications of proteins, and a delayed
tolerance which lasts for 1–3 days and is mediated by genetic
reprogramming (Stevens et al., 2014). Multiple studies have
demonstrated that 2-OG analogs protect tissue from ischaemic
injury when given after ischaemia, so called post-conditioning
(Nagel et al., 2011; Reisch et al., 2014). Post-conditioning
protection is associated with reduced ROS formation (Reisch
et al., 2014). Ong et al. (2014) found that activation of the
HIF pathway mediated inhibition of the mPTP thereby reduced
cell death. The authors reasoned that mPTP inhibition was
dependent on hexokinase II, which is a HIF downstream gene
(Suski et al., 2012). Moreover, the study also identified increased
PDK1 expression resulting in decreased ROS formation (Kim
et al., 2006). Conversely, inhibition of HIF1α expression by
HIF1α specific small interfering RNA (siRNA) transfection
increased ROS generation and cell death (Guo et al., 2009).
Another study conducted by Ockaili et al. (2005) found
HIF-1 activation upregulated heme oxygenase (HO)-1 during
reperfusion. Upregulation of HO-1 attenuated pro-inflammatory
cytokine production by microvascular endothelium. HIF1
activation upregulated phagocytic activities in microglia
selectively under hypoxic conditions, regulating the functions
of microglia such as chemotaxis and production of cytokines or
ROS (Bok et al., 2017).
Neuronal specific HIF1α knock out mice has worse
neurological outcome and larger infarct volume following
transient focal cerebral ischaemia – the middle cerebral artery
occlusion (MCAO) (30 min) compared to their WT littermates
(Baranova et al., 2007), however, Helton et al. (2005) showed
Frontiers in Cell and Developmental Biology | www.frontiersin.org 6 October 2018 | Volume 6 | Article 132
fcell-06-00132 October 8, 2018 Time: 15:41 # 7
Chen et al. ROS in the Brain
FIGURE 2 | The interaction between ROS formation and HIF activation at different oxygen concentrations. (A) In hypoxia, HIF is stabilized and ROS formation is
increased. While increased ROS levels in cells contribute to further stabilization of HIF, HIF stabilization can either reduce or increase ROS formation; (B) In physioxia,
HIFα is continuously produced but is quickly degraded and HIF is not detectable, while ROS formation is minimum as pro-oxidant and anti-oxidant substances are
balanced; and (C) In hyperoxia, ROS is elevated while HIF stabilization is prevented due to PHD inhibition. However, HIF stabilization can be induced through ROS
while HIF stabilization can either reduce or increase ROS formation.
brain specific HIF1α knock out has better outcome following
global ischaemia – bilateral common carotid artery occlusion
(75 min) due to reduced apoptosis. Barteczek et al. (2017)
did transient MCAO (30–60 min) on Hif1af /f , Hif2af /f , and
Hif1a/Hif2aff /ff mice, and found no significant changes in infarct
volume between the Hifa single knockout compared to their
respective WT mice, probably due to a mutual compensation in
the mice. Hif1a/Hif2a double knockout mice initially performed
better following MCAO, but became significantly more impaired
after 72 h with increased apoptosis and reduced angiogenesis,
indicating a benefit of HIF-pathway inhibition in neurons in
the very acute phase after ischemic stroke. The effect of HIF on
ischaemic brain may vary depending on the severity, duration of
stroke as well as the time and amounts of HIF activation. The HIF
can promote the transcription of multiple pro-survival proteins
and exerts neuroprotection in ischaemic stroke (Guo, 2017; Luo
et al., 2017; Yang et al., 2017), but also involve in post-stroke
inflammatory responses, apoptosis and BBB disruption (Zhang
et al., 2016).
Compared with the HIFα single knock out mice, the
PHD single isoform knock out mice have consistent outcomes
following cerebral ischaemia. We have performed transient
MCAO (45 min) on PHD1−/−, PHD2+/− (as homozygous
PHD2 deficiency is embryonically lethal), and PHD3−/− mice.
We reported both PHD1−/− and PHD2+/− mice had better
neurological outcomes following the MCAO, and the PHD2+/−
mice had significant better blood reperfusion when the filament
was withdrawn (Chen et al., 2012). Quaegebeur et al. (2016)
later performed permanent MCAO (24 h) without reperfusion
on PHD1−/−, PHD2NKO (a neural specific PHD2 deficient
mice), and PHD3−/− mice. They reported that PHD1−/− mice
had smaller infarct volume and better neurological outcomes
compared to the WT mice. The authors found the PHD1−/−
neurons increased their redox buffering capacity to scavenge
ROS in ischemia/reperfusion, and enhanced glucose flux through
the oxidative pentose phosphate pathway by diverting glucose
away from glycolysis. The authors concluded the protection in
the PHD1−/− mice might be caused by reprogramming glucose
metabolism in neurons rather than the vasculature change in
mouse brain. Both PHD2NKO mice and PHD3−/− mice had
similar infarct volume and neurological function compared
to their WT littermates following the MCAO. In agreement,
selective inhibition of PHD1 by RNA interference to PHD1
in HT22 cells prevented oxidative death, independent of HIF-
1α and CREB (Siddiq et al., 2009). Nevertheless, Li et al.
(2016) report neuronal specific PHD2 knock out mice showed
better neurological outcomes and smaller infarct volume in an
HIF dependent manner following permanent MCAO for either
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7 days (sub-acute stage) or 30 days (chronic stage). These mice
also showed less brain injuries following a transient MCAO
(Kunze et al., 2012). Taken together it is possible that chronic
pharmacological inhibition of PHD2, and perhaps PHD1, would
stimulate adaptations that provide protection against damage
from a subsequent stroke.
These effects in genetically modified mice are seen following
lifelong HIFα or PHD deficiency and thus reflect a composite
of developmental changes, affecting features such as vessel
density, overall sympathetic tone, metabolism and immunity
(Chen et al., 2012). A pharmacological approach for ischaemic
cerebral tolerance is clinically appealing due to its non-
invasive application. Currently, there is no drug specifically
inhibits a single PHD isoform. Researchers focus on generating
chemicals targeting the PHD2, as it is a main PHD isoform
settling the HIF level in normoxia (Yeh et al., 2017). Four
HIF hydroxylase inhibitors (FG4592, GSK1278863, Bay85-3934,
and AKB-6548) have progressed to Phase II or III clinical
trials for treating anemia in patients with chronic kidney
disease (Chan et al., 2016). The use of small molecule HIF
hydroxylase inhibitors has many advantages such as low price,
good compliance, and few allergic reactions (Gupta and Wish,
2017).
A number HIF PHD inhibitors have been applied in
ischaemic stroke models either in vivo or in vitro, where
these compounds (GSK360A, FG4497, FG2216, DMOG, and
DFO) offered neuroprotection (Li et al., 2008; Nagel et al.,
2011; Zhao and Rempe, 2011; Ogle et al., 2012; Chen et al.,
2014; Reisch et al., 2014; Zhou J. et al., 2017). The systemic
application of the hydroxylase inhibitors dimethyloxalylglycine
(DMOG) or FG2216 before onset of cerebral ischaemia led to
increased acute cerebral tissue preservation (Nagel et al., 2011;
Chen et al., 2014). Furthermore, post-treatment with DMOG
or FG4574 attenuated sensorimotor dysfunction in mice 3 or
7 days after ischaemia-reperfusion injury (Kunze et al., 2012;
Ogle et al., 2012). The inhibition of HIF hydroxylase not only
exerts pleiotropic neuroprotective effects as a consequence of
HIF induction (Lee et al., 2009), but also has anti-oxidant
(Kunze et al., 2012) and anti-inflammatory effects (Scholz
et al., 2013). HIF hydroxylase inhibition engages multiple
downstream effector pathways indicating that this is a promising
therapeutic intervention that that can challenge the heterogeneity
in stroke pathophysiology present in humans. Because the HIF
hydroxylase inhibition leverages endogenous adaptive programs,
the breadth of the response will not lead to an increased
likelihood of toxicity. Nevertheless, the inhibition of PHD was
found to lead to reduced neurite growth and functional recoveries
after brain ischaemic injury as PHDs were shown to have
an important role in the formation of compensatory axonal
networks (Miyake et al., 2015). In a severe global cerebral
ischaemia model (unilateral carotid artery ligation in neonatal
mice) in neonatal rats, DMOG worsen the outcome due to
increased BBB permeability and brain edema while 2Me2 (2-
methoxyestradiol), a HIF-1α inhibitor, improved the neurological
outcome (Chen et al., 2008). Yeh et al. (2011) applied 2Me2 to
neurons 8 h after OGD increased neuron damage and decreased
vascular endothelial growth factor (VEGF) expression, while
applying 2Me2 at 0.5 h after the OGD showed opposite effects.
Chen et al. (2010) found 2ME and YC-1 (another HIF inhibitor)
reduced infarct volume and ameliorated neurological deficits
in rats following transient MCAO (90 min). However, both
2Me2 and YC-1 decreased the recovery in the morphology of
astrocyte and increased astrocyte death during severe hypoxia
(0.2% O2), indicating the expression of HIF1α under hypoxia has
a protective effect on astrocyte for maintaining cell morphology
and viability (Badawi et al., 2012). The PHD inhibitors were
not as effective as the proteasome inhibitors, as the PHD
inhibitors only block hydroxylation of HIF1α and the 26 S
pathway activity, but not the 20 S pathway, thus only provided
a partial effect on HIF accumulation (Badawi and Shi, 2017).
It is important to emphasize that HIF hydroxylase inhibition
does not equal HIF activation. HIFs are only one of a number
of growing substrates known to modulate via HIF hydroxylase
activity (Mikhaylova et al., 2008; Karuppagounder and Ratan,
2012).
CONCLUSION
Hypoxia inducible factor accumulation and ROS formation occur
simultaneously in hypoxia. HIF accumulation during hypoxia
could either induce or inhibit ROS formation through its
downstream transcriptional targets, while ROS increases HIF
accumulation during both hypoxia and reperfusion (Figure 2).
Although antioxidation is a therapeutic approach for treating
ischaemic diseases, the role of HIF during reperfusion is
still debatable. Developing further understanding of the HIF
pathway and its relation with ROS may allow for the
advancement of pharmacological therapies that protect against
ischaemic diseases, e.g., ischaemic stroke. HIF activation by
potent, selective small molecule PHD inhibitors can become
effective therapy for ischaemic stroke, given its antioxidation,
anti-inflammatory properties in addition to its pro-survival
signaling.
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